Sanofi signs $1.45bn deal to acquire Kymab, expanding its immune-therapy pipeline

In a significant move to bolster its immuno-oncology and immune-mediated disease portfolio, Sanofi has acquired Kymab, a UK-based clinical-stage biopharma company, in a deal valued ... Read More